Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer

PURPOSE: Pembrolizumab demonstrated antitumor activity in programmed death ligand 1 positive (combined positive score (CPS) ≥ 1) gastric/gastroesophageal junction cancer in KEYNOTE-059 (third line or beyond), KEYNOTE-061 (second line), and KEYNOTE-062 (first line). We characterized efficacy and safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Muro, Kei, Shitara, Kohei, Yamaguchi, Kensei, Yoshikawa, Takaki, Satake, Hironaga, Hara, Hiroki, Sugimoto, Naotoshi, Machida, Nozomu, Goto, Masahiro, Kawakami, Hisato, Amagai, Kenji, Omuro, Yasushi, Esaki, Taito, Hironaka, Shuichi, Nishina, Tomohiro, Komatsu, Yoshito, Matsubara, Hisahiro, Shiratori, Shinichi, Han, Shirong, Satoh, Taroh, Ohtsu, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613141/
https://www.ncbi.nlm.nih.gov/pubmed/37037952
http://dx.doi.org/10.1007/s12029-023-00920-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613141/
https://www.ncbi.nlm.nih.gov/pubmed/37037952
http://dx.doi.org/10.1007/s12029-023-00920-9

Ejemplares similares